Download PDF
Int J Angiol 2016; 25(05): e100-e105
DOI: 10.1055/s-0035-1548557
Case Report
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Bilateral Superficial Femoral Artery Thrombosis in a 15-Year-Old Caucasian Male with Homozygous Prothrombin G20210A Genotype and Associated Antiphospholipid Syndrome

Uzung Yoon
1   Department of Surgery, Hofstra North Shore–Long Island Jewish School of Medicine, Manhasset, New York
,
LaiLai Kwok
2   Lincoln Memorial University, DeBusk College of Osteopathic Medicine, Harrogate, Tennessee
,
Ingo Flessenkaemper
3   Helios Klinikum Emil von Behring, Chairman of Vascular and Endovascular Surgery, Berlin, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
23 March 2015 (online)

    Permissions and Reprints

Abstract

Prothrombin mutation was usually associated with other well-established predisposing factors for venous thrombosis such as antiphospholipid antibodies. Recently, even isolated prothrombin gene mutation G20210A has been reported to present severe or unusual vein thrombosis. Less clear is the role of prothrombin mutation in the formation of arterial thrombosis. We present a case of a 15-year-old healthy White male with acute bilateral femoral artery thrombosis. The patient presented with increasing left leg pain for about 1 week. He was a physically very active teenager with a new onset of leg pain aggravated by exercise. Physical examination revealed a pale and cold left foot with dorsal foot necrosis (2 × 2 cm) that started 2 days ago. In addition, he complained of moderate rest pain. No symptoms were noticed on the right lower extremity. The ankle brachial index was 0.3 on the left and 0.6 on the right. Duplex sonography showed bilateral superficial femoral artery thrombosis, which was confirmed by angiography. Subsequently, he undergoes left superficial femoral and popliteal artery lysis with rt-PA (Actilyse boehringer ingelheim, Ingelheim am Rhein, Germany) and full heparinization. Treatment was discontinued after 24 hours with no significant improvement of symptoms. Full anticoagulation with Coumadin (Bristol-Myers Squibb Company, New York, NY) and alprostadil (Prostavasin UCB, Brussels, Belgium) infusion for 2 weeks was initiated and eventually patient's symptoms improved. Laboratory testing revealed a homozygous prothrombin G20210A mutation and antiphospholipid syndrome. Homozygous prothrombin G20210A mutation in conjunction with antiphospholipid syndrome is a rare combination of coagulation disorder. Early intervention with full anticoagulation and subsequent lifelong anticoagulation should be considered in treatment strategy.

Keywords

homozygous prothrombin mutation - G20210A - antiphospholipid syndrome - femoral artery thrombosis
 

  • Reference

  • 1 Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG ; TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 (Suppl S): S5-S67
    CrossrefPubMedGoogle Scholar
  • 2 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88 (10) 3698-3703
    CrossrefPubMedGoogle Scholar
  • 3 Rosendaal FR, Doggen CJ, Zivelin A , et al. Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 1998; 79 (4) 706-708
    Article in Thieme ConnectPubMedGoogle Scholar
  • 4 Nguyen A. Prothrombin G20210A polymorphism and thrombophilia. Mayo Clin Proc 2000; 75 (6) 595-604
    CrossrefPubMedGoogle Scholar
  • 5 Souto JC, Coll I, Llobet D , et al. The prothrombin 20210A allele is the most prevalent genetic risk factor for venous thromboembolism in the Spanish population. Thromb Haemost 1998; 80 (3) 366-369
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Campello E, Spiezia L, Radu CM , et al. Circulating microparticles in carriers of prothrombin G20210A mutation. Thromb Haemost 2014; 112 (3) 432-437
    Article in Thieme ConnectPubMedGoogle Scholar
  • 7 Balian A, Veyradier A, Naveau S , et al. Prothrombin 20210G/A mutation in two patients with mesenteric ischemia. Dig Dis Sci 1999; 44 (9) 1910-1913
    CrossrefPubMedGoogle Scholar
  • 8 Zuazu-Jausoro I, Sanchez I, Fernandez MC, Corral J, Gonzalez-Conejero R, Vicente V. Portal and mesenteric venous thrombosis in a patient heterozygous for the 20210 A allele of the prothrombin gene. Haematologica 1998; 83 (12) 1129-1130
    PubMedGoogle Scholar
  • 9 Hertzberg MS, Underwood T, Favaloro EJ. Mesenteric vein thrombosis secondary to combined protein C deficiency and double heterozygosity for factor V Leiden and prothrombin G20210A. Am J Hematol 1999; 62 (3) 199-200
    CrossrefPubMedGoogle Scholar
  • 10 Girolami A, Simioni P, Tormene D, Scarano L. Two additional homozygous patients for the 20210 prothrombin polymorphism with no venous thrombosis. Thromb Res 1999; 96 (5) 415-417
    CrossrefPubMedGoogle Scholar
  • 11 Martlew VJ, Perez-Casal M, Alfirevic Z, Toh CH. What clinical significance has the presence of the homozygous G20210A prothrombin gene mutation in a healthy woman?. Thromb Haemost 2000; 84 (2) 355-356
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Alatri A, Franchi F, Moia M. Homozygous G20210A prothrombin gene mutation without thromboembolic events: a case report. Thromb Haemost 1998; 80 (6) 1028-1029
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 González Ordóñez AJ, Medina Rodriguez JM, Fernández Alvarez CR, Macias Robles MD, Coto García E. A patient homozygous for mutation 20210A in the prothrombin gene with venous thrombosis and transient ischemic attacks of thrombotic origin. Haematologica 1998; 83 (11) 1050-1051
    PubMedGoogle Scholar
  • 14 Zawadzki C, Gaveriaux V, Trillot N , et al. Homozygous G20210A transition in the prothrombin gene associated with severe venous thrombotic disease: two cases in a French family. Thromb Haemost 1998; 80 (6) 1027-1028
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Bauduer F, Claracq M, Orgogozo F, Mariescu M, Ducout L, Freyburger G. Mesenteric venous thrombosis in a 40-year-old man with homozygous factor II G20210A mutation. Blood Coagul Fibrinolysis 2000; 11 (8) 785-786
    CrossrefPubMedGoogle Scholar
  • 16 Eikelboom JW, Ivey L, Ivey J, Baker RI. Familial thrombophilia and the prothrombin 20210A mutation: association with increased thrombin generation and unusual thrombosis. Blood Coagul Fibrinolysis 1999; 10 (1) 1-5
    CrossrefPubMedGoogle Scholar
  • 17 Klein L, Bhardwaj V, Gebara B. Cerebral venous sinus thrombosis in a neonate with homozygous prothrombin G20210A genotype. J Perinatol 2004; 24 (12) 797-799
    CrossrefPubMedGoogle Scholar
  • 18 Scott CM, Hanley JP, Ludlam CA, Stirling D. Homozygosity for a factor II polymorphism associated with thrombosis during pregnancy. [abstract] Thromb Haemost 1997; 77: 770
    PubMedGoogle Scholar
  • 19 Kosch A, Junker R, Wermes C, Nowak-Göttl U. Recurrent pulmonary embolism in a 13-year-old male homozygous for the prothrombin G20210A mutation combined with protein S deficiency and increased lipoprotein (a). Thromb Res 2002; 105 (1) 49-53
    CrossrefPubMedGoogle Scholar
  • 20 Vayá A, García M, Mira Y , et al. Homozygous 20210G/A prothrombin gene mutation associated with bilateral iliac vein thrombosis: a case report. Thromb Res 2001; 104 (4) 293-296
    CrossrefPubMedGoogle Scholar
  • 21 Young G, Manco-Johnson M, Gill JC , et al. Clinical manifestations of the prothrombin G20210A mutation in children: a pediatric coagulation consortium study. J Thromb Haemost 2003; 1 (5) 958-962
    CrossrefPubMedGoogle Scholar
  • 22 Kling F, Macarez R, Robinet A, Kouassi FX, Colin J. [Mixed retinal thrombosis in a patient carrying prothrombin gene mutation in a homozygote state]. J Fr Ophtalmol 1999; 22 (9) 979-981
    PubMedGoogle Scholar
  • 23 Berridge DC, Kessel DO, Robertson I. Surgery versus thrombolysis for initial management of acute limb ischaemia. Cochrane Database Syst Rev 2013; 6: CD002784
    PubMedGoogle Scholar
  • 24 Taha AG, Byrne RM, Avgerinos ED, Marone LK, Makaroun MS, Chaer RA. Comparative effectiveness of endovascular versus surgical revascularization for acute lower extremity ischemia. J Vasc Surg 2015; 61 (1) 147-154
    CrossrefPubMedGoogle Scholar
  • 25 Karnabatidis D, Spiliopoulos S, Tsetis D, Siablis D. Quality improvement guidelines for percutaneous catheter-directed intra-arterial thrombolysis and mechanical thrombectomy for acute lower-limb ischemia. Cardiovasc Intervent Radiol 2011; 34 (6) 1123-1136
    CrossrefPubMedGoogle Scholar
  • 26 Doomernik DE, Schrijver AM, Zeebregts CJ, de Vries JP, Reijnen MM. Advancements in catheter-directed ultrasound-accelerated thrombolysis. J Endovasc Ther 2011; 18 (3) 418-434
    CrossrefPubMedGoogle Scholar
  • 27 Rutherford RB, Baker JD, Ernst C , et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26 (3) 517-538
    CrossrefPubMedGoogle Scholar
  • 28 Schrijver AM, Reijnen MM, van Oostayen JA , et al. Dutch randomized trial comparing standard catheter-directed thrombolysis versus ultrasound-accelerated thrombolysis for thromboembolic infrainguinal disease (DUET): design and rationale. Trials 2011; 12: 20
    CrossrefPubMedGoogle Scholar
  • 29 Crowther MA, Ginsberg JS, Julian J , et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349 (12) 1133-1138
    CrossrefPubMedGoogle Scholar
  • 30 Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117 (4) 303-308
    CrossrefPubMedGoogle Scholar